After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing
February 16, 2011
After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing
As the company looks to 2011 and beyond, it plans to continue to invest in growing its test menu, expanding its business overseas, and advancing sequencing efforts to ultimately develop the next generation of Oncotype DX tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genomic Health Updates Investors on Timeline for DCIS, Colon Cancer, Prostate Cancer Tests
September 29, 2010 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter - Genomic Health Partners with OncoMed to Grow Companion Dx, NGS Reach
May 9, 2012 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter - Genomic Health Attributes Q3 Revenue Growth to Strong International Test Adoption
November 14, 2012 / Pharmacogenomics Reporter